Ftse Mib
34.460,52
0,00%
DAX
18.682,11
0,00%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.497,72
0,57%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Karyopharm Therapeutics Inc (KPTI) Karyopharm Therapeutics Inc (KPTI) Notizie

KPTI

Karyopharm Therapeutics (KPTI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KPTI
DataOraFonteTitoloSimboloCompagnia
14/05/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422:05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413:30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413:30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
07/05/202422:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/05/202422:30PR Newswire (US)Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/05/202422:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/04/202422:01PR Newswire (US)Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202422:05PR Newswire (US)Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202413:43Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202413:30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
22/02/202413:00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
14/02/202416:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/01/202414:30PR Newswire (US)Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 ObjectivesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/01/202413:00PR Newswire (US)Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
11/12/202302:15PR Newswire (US)Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)NASDAQ:KPTIKaryopharm Therapeutics Inc
08/11/202322:05PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/11/202313:00PR Newswire (US)Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyNASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202314:20PR Newswire (US)Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)NASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202312:30PR Newswire (US)Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202313:00PR Newswire (US)Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:KPTIKaryopharm Therapeutics Inc
26/10/202313:00PR Newswire (US)Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
26/09/202313:00PR Newswire (US)Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual MeetingsNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202314:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202314:00PR Newswire (US)Karyopharm Appoints Zhen Su, MD, MBA to its Board of DirectorsNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202314:59Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202313:30PR Newswire (US)Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
26/07/202313:00PR Newswire (US)Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
25/07/202321:00PR Newswire (US)Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial CancerNASDAQ:KPTIKaryopharm Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KPTI

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network